Product Overview
GHRP-6 arrives from Dragon Pharma as a single lyophilised 10 mg vial, a freeze-dried hexapeptide that has to be dissolved in a solvent before any bench work starts. Chemically it is a synthetic analogue of met-enkephalin carrying the development code SKF-110679, but the structural resemblance to an opioid peptide is misleading: reviewed sources state that it has no opioid activity at all. Its actual target is the ghrelin receptor (GHSR), which places it in the growth hormone secretagogue family and gives it a mechanism unrelated to growth hormone releasing hormone.
The pharmacokinetic picture here is unusually solid for a research peptide, because it comes from human work rather than from animal models. A study in nine healthy volunteers puts the terminal elimination half-life at 2.5 plus or minus 1.1 hours and the distribution phase at 7.6 plus or minus 1.9 minutes, so an injected dose produces a growth hormone pulse that peaks quickly and fades within hours. Oral absorption is under one percent, which is the reason every published protocol in the sources is injectable and the reason oral capsules are not a substitute.
Two consequences follow from those numbers. First, a single daily injection cannot hold a level, so the pattern in research writing is small fragmented doses, often placed before sleep. Second, growth hormone secretagogues are usually studied together with a releasing-hormone signal, because the two act through different receptors; inside this section that partner is CJC-1295 DAC. Users whose priority is a secretagogue that leaves cortisol alone look instead at Ipamorelin 5mg, and Hexarelin 5 mg is the neighbouring hexapeptide with a different sequence and a different side-effect profile.
Vial Arithmetic and Reconstitution
Nothing about this product is a human protocol. The lines below are solvent arithmetic for the 10 mg vial and the published figures behind them, and the milligram-per-millilitre numbers depend entirely on how much water is added.
| Solvent | Bacteriostatic water run down the wall of the vial; do not shake the lyophilisate |
| 10 mg in 2 ml | 5 mg/ml. On a U-100 scale 0.1 ml is 10 units and carries 500 mcg |
| 10 mg in 5 ml | 2 mg/ml. Ten units then correspond to 200 mcg |
| 5 mg in 2 ml | 2.5 mg/ml, where ten units equal 250 mcg; quoted here because the smaller vial follows the same arithmetic |
| Human kinetic anchor | Terminal half-life 2.5 plus or minus 1.1 hours and distribution phase 7.6 plus or minus 1.9 minutes in nine healthy volunteers |
| Oral route | Bioavailability below one percent; no oral schedule is supported by the literature |
| Female | The sources behind this page contain no verified female schedule, and no licensed human schedule exists for men either |
Ghrelin-Arm Protocols
Research writing groups this peptide in three ways. None of them was tested in a controlled trial as a combination, so they are study arrangements rather than evidence.
What to Expect
- Growth hormone pulse. Plasma growth hormone rises inside the first hour and the response decays over the following hours, which matches the 2.5 hour terminal half-life.
- Hunger. The loudest signal in the group. Increased appetite is described as the defining feature of GHRP-6 rather than as an unwanted effect.
- Stress-hormone axis. ACTH and cortisol are stimulated, and this is the direct difference from ipamorelin, which does not do that.
- Injection frequency decides the curve. With a short half-life the frequency governs the result far more than the size of any single dose.
- No oral shortcut. Absorption by mouth is under one percent, so the swallow-it option does not exist.
- Regulatory ceiling. No ATC code and no pharmaceutical dosage form; the material is sold as a research peptide and is prohibited in sport at all times under class S2.
Side Effects and Management
The profile is dominated by the appetite signal and by the hormonal axis the peptide switches on. Figures below are class-level observations, because no separate statistics for GHRP-6 were found in the sources.
Monitoring, Stability and No PCT
There is no post-cycle protocol to run for this material, because it does not suppress natural testosterone production. What matters instead is the observation log and the way the vial is kept.
Every vial needs solvent, so Bacteriostatic water is the companion purchase. For comparison work on the hormone itself rather than on the release mechanism, Dragontropin supplies exogenous somatropin, and IGF-1 LR3 sits one step further down the same pathway. Growth hormone releasing factors and their secretagogues are prohibited at all times in sport under WADA class S2, which is worth knowing before any sample is taken.
